Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NC762

Monoclonal antibody · Immune activation, directed at B7-H4 (VTCN1) · developed by NextCure

Phase 1/2 Most advanced trial (none active)
NXTC Developer
1 Registered trials

What is NC762?

NC762 is a humanized IgG1 kappa monoclonal antibody that binds B7-H4 on the surface of tumor cells. Its Fc region carries three point mutations that enhance binding to CD16a on natural killer cells, increasing antibody-dependent cellular cytotoxicity against B7-H4-expressing cells. It is studied in advanced or metastatic solid tumors, ovarian cancer, non-small cell lung cancer and breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
B7-H4 (VTCN1), FcgammaRIIIa (CD16a) (FCGR3A) (binding partner it blocks)
Mechanism
Immune activation, directed at B7-H4 (VTCN1)
Pathways
antibody-dependent cellular cytotoxicity (ADCC), inhibition of tumor cell proliferation
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04875806 Phase 1/2 Advanced or Metastatic Solid Tumors Terminated NXTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid TumorsBreast CancerNon-small Cell Lung CancerOvarian Cancer

Other drugs acting on VTCN1

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind NC762

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.